Welcome to our dedicated page for Editas Medicine news (Ticker: $EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Editas Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Editas Medicine's position in the market.
Editas Medicine reported financial results for the first quarter of 2024, highlighting completion of adult cohort enrollment and patient dosing in the adolescent cohort for the RUBY trial for severe sickle cell disease. They are on track to present clinical data in mid-2024. The company is also enrolling patients in the EdiTHAL trial for transfusion-dependent beta thalassemia, presenting pre-clinical data at ASGCT, maintaining a strong financial position until 2026, and extending collaboration with Bristol Myers Squibb. Editas Medicine aims to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.
Editas Medicine, Inc. (Nasdaq: EDIT) will host a conference call on May 8, 2024, to discuss first quarter 2024 results and provide a corporate update. The company will also participate in several upcoming investor events, including the Bank of America Health Care Conference and RBC Capital Markets Global Healthcare Conference.
Editas Medicine, Inc. (Nasdaq: EDIT) has extended its collaboration with Bristol Myers Squibb (NYSE: BMY) for two more years to research, develop, and commercialize alpha-beta T cell medicines for cancer and autoimmune diseases. Bristol Myers Squibb has opted into 13 programs across 11 gene targets, with potential milestone payments and royalties for Editas Medicine. The collaboration aims to create the next generation of allogeneic medicines to combat various cancers.